VENITI™, Inc. Announces First U.S. Patients Enrolled in VIRTUS Trial
ST. LOUIS, Dec. 1, 2014 /PRNewswire/ -- VENITI, Inc., a company dedicated to advancing the treatment of venous disease, announced that it has enrolled the first United States patients in the VIRTUS trial of the VENITI VICI™ Venous Stent System. The four procedures were performed at two sites, including the Heart and Vascular Center, St. Joseph Hospital, Orange, CA.
"We are pleased to be among the first centers to treat patients using the VICI Venous Stent System," said Mahmood Razavi, M.D., Director for Clinical Trials & Research and Co-Principal Investigator for the VIRTUS trial. "In treating patients with venous disease, we must address the specific challenges encountered as compared to those with arterial disease. We are excited to participate in the VIRTUS trial of a stent, designed from its inception, for use in the venous system."
Scott Solano, VENITI, Inc. President and CEO commented, "The beginning of enrollment in the VIRTUS trial is a positive milestone for the Company. Based on the experience of physicians in Europe, both in clinical and commercial cases, Dr. Razavi's experience met our expectations. We look forward to continued collaboration with our sites in the U.S. and Europe."
The VICI Venous Stent System was designed to be compatible with the unique anatomy and pathophysiology of the venous system, including crush resistance, vessel coverage and flexibility. It is intended for use in veins of the lower extremities and pelvis, including the iliac and common femoral veins, in patients who exhibit symptomatic venous outflow obstruction. This condition is frequently associated with disorders of the lower extremities, such as varicose veins and venous ulcers. These disorders affect hundreds of thousands of people around the world.
About VENITI, Inc.
VENITI, Inc. is an early-stage commercialization company that is headquartered in St. Louis, MO and has established an innovation center for Research & Development and Operations in Fremont, CA. Founded in 2010, it is dedicated to advancing the treatment of venous disease through innovative technology and solutions. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI™ Venous Stent System. In launching the Venous Stent System, VENITI partners with individuals and companies with leadership roles in the development and training for therapies to provide advancement of care in venous disease. Through this, and other innovative technology, VENITI will achieve results that set it apart in addressing the challenges specific to the venous system and venous disease The Venous Stent System is CE marked under the European Medical Devices Directive (93/42/EEC) and commercially available in Europe. CAUTION: Investigational device. Limited by United States law to investigational use. VENITI and VENITI VICI are trademarks of VENITI, Inc. ©2014 VENITI, Inc. All Rights Reserved. Produced in the U.S. For more information, call +1 (314) 282-3753 or visit www.veniti.com.
Company Contact:
Scott Solano
+1 (314) 338 3019
[email protected]
Media Contact:
Rodney Marcy
+1 (303) 885-7546
[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veniti-inc-announces-first-us-patients-enrolled-in-virtus-trial-300002269.html
SOURCE VENITI, Inc.
Share this article